PPARδ Expression and Prognosis in Resected Pancreatic Cancer: A Retrospective Single-Centre Study

Pancreatic cancer is an extremely deadly form of cancer with few curative options and poor long-term outcomes. Recent research has focused on the role of nuclear receptors, such as PPAR{delta}, in tumor progression. In a recent study, researchers retrospectively examined 25 resected pancreatic cancer specimens from patients who underwent Whipple's procedure (pancreatoduodenectomy) between 2000 and 2009.

Immunohistochemistry was performed to detect PPAR{delta} expression in the tumors and stromal tissues. The results showed that PPAR{delta} was expressed in the majority of the samples analyzed.

The researchers then correlated the PPAR{delta} expression with clinicopathological features and survival data of the patients. Their preliminary findings suggest that higher levels of PPAR{delta} expression are associated with more aggressive tumor biology and poorer survival rates in pancreatic cancer patients. This study's findings indicate that PPAR{delta} immunohistochemistry could potentially identify a subset of pancreatic cancers with more aggressive characteristics.

However, the researchers emphasize that further, larger studies are necessary to validate these findings and determine the clinical significance of PPAR{delta} expression in pancreatic cancer prognosis.